María Ochoa-de-Olza

Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

Patrick Schöffski, Daniel Shao-Weng Tan, Miguel Martín et al. · Journal for ImmunoTherapy of Cancer · 2022 · 156 citations · Full text

Medicine, Oncology, Pharmacology +17

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients

Gabriela Jiménez-Valerio, Mar Martínez‐Lozano, Nicklas Bassani et al. · Cell Reports · 2016 · 119 citations · Full text

Medicine, Oncology, Pharmacology +17

OX40 Agonist BMS-986178 Alone or in Combination With Nivolumab and/or Ipilimumab in Patients With Advanced Solid Tumors

Martin Gutierrez, Víctor Moreno, Kimberley M. Heinhuis et al. · Clinical Cancer Research · 2020 · 110 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

Marta Ligero, Alonso García-Ruiz, Cristina Viaplana et al. · Radiology · 2021 · 105 citations

Medicine, Oncology, Radiology +17

Response to tumor-infiltrating lymphocyte adoptive therapy is associated with preexisting CD8 ⁺ T-myeloid cell networks in melanoma

David Barras, Eleonora Ghisoni, Johanna Chiffelle et al. · Science Immunology · 2024 · 91 citations · Full text

Medicine, Immunology, Oncology +11